Carlsson M, Svensson A, Carlsson A
Department of Pharmacology, University of Göteborg, Sweden.
Naunyn Schmiedebergs Arch Pharmacol. 1991 Jun;343(6):568-73. doi: 10.1007/BF00184286.
The purpose of the present investigation was to study the effects of simultaneous manipulations of central cholinergic, adrenergic and glutamatergic systems on locomotion in an animal model of Parkinson's disease. Mice were deprived of their monoamine stores by pretreatment with the monoamine depleter reserpine and the catecholamine synthesis inhibitor alpha-methyl-p-tyrosine, given 18 h and 60 min, respectively, before the acute experiment. Traditionally, only dopaminergic agonists have been shown to reverse the akinesia thus produced. However, in the present study it is demonstrated that if a muscarine receptor antagonist (atropine or biperiden) is combined with an alpha-adrenergic agonist/alpha-adrenergic agonist precursor (clonidine or L-alpha-methyl-dopa), a marked locomotor stimulation can be achieved, although either agent given alone is ineffective. Adding an NMDA antagonist (MK-801, ketamine or SDZ EAA 494) to the combination biperiden + clonidine resulted in further potentiation of the locomotor stimulatory effects.
本研究的目的是在帕金森病动物模型中,研究同时操纵中枢胆碱能、肾上腺素能和谷氨酸能系统对运动的影响。在急性实验前18小时和60分钟,分别用单胺耗竭剂利血平和儿茶酚胺合成抑制剂α-甲基对酪氨酸对小鼠进行预处理,使其单胺储备耗尽。传统上,只有多巴胺能激动剂已被证明可逆转由此产生的运动不能。然而,在本研究中证明,如果将毒蕈碱受体拮抗剂(阿托品或安坦)与α-肾上腺素能激动剂/α-肾上腺素能激动剂前体(可乐定或L-α-甲基多巴)联合使用,尽管单独使用任何一种药物均无效,但仍可实现明显的运动刺激。将NMDA拮抗剂(MK-801、氯胺酮或SDZ EAA 494)添加到安坦+可乐定的组合中,可进一步增强运动刺激作用。